Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma
Oslo, Norway, 26 October 2018 Nordic Nanovector ASA (OSE: NANO) announces that the first clinical site in the United States (in Long Beach, CA) for the pivotal PARADIGME trial has been initiated to enable enrolment of patients. PARADIGME is a global randomised Phase 2b clinical trial comparing two Betalutin® (177Lu-satetraxetan-lilotomab) dosing regimens (15 MBq/kg Betalutin® following 40mg lilotomab pre-dosing; 20 MBq/kg Betalutin® following 100mg/m2 lilotomab pre-dosing) in 3L follicular lymphoma patients who are refractory to anti-CD20 therapy (including rituximab). The trial aims